Equities research analysts expect that OraSure Technologies, Inc. (NASDAQ:OSUR) will report $45.27 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for OraSure Technologies’ earnings. The lowest sales estimate is $45.03 million and the highest is $45.50 million. OraSure Technologies reported sales of $35.50 million in the same quarter last year, which would suggest a positive year over year growth rate of 27.5%. The business is scheduled to issue its next earnings results on Wednesday, February 14th.

On average, analysts expect that OraSure Technologies will report full-year sales of $45.27 million for the current fiscal year, with estimates ranging from $160.07 million to $160.60 million. For the next financial year, analysts anticipate that the firm will report sales of $171.08 million per share, with estimates ranging from $169.15 million to $173.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The company had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. During the same period in the prior year, the company earned $0.11 earnings per share. The firm’s revenue was up 31.0% on a year-over-year basis.

Several research firms have commented on OSUR. Canaccord Genuity reaffirmed a “buy” rating and issued a $22.00 price target on shares of OraSure Technologies in a report on Tuesday, September 19th. Zacks Investment Research raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, December 2nd. ValuEngine lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, Jefferies Group reissued a “buy” rating and set a $20.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 12th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $18.21.

Shares of OraSure Technologies (NASDAQ:OSUR) opened at $17.37 on Monday. OraSure Technologies has a 1-year low of $8.39 and a 1-year high of $23.01. The company has a market cap of $1,053.46, a price-to-earnings ratio of 33.40, a price-to-earnings-growth ratio of 3.34 and a beta of 1.28.

In related news, CEO Douglas A. Michels sold 22,923 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total transaction of $527,229.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mara G. Aspinall purchased 5,000 shares of OraSure Technologies stock in a transaction that occurred on Tuesday, November 7th. The shares were bought at an average price of $14.23 per share, with a total value of $71,150.00. Following the transaction, the director now owns 5,000 shares in the company, valued at $71,150. The disclosure for this purchase can be found here. Corporate insiders own 6.40% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in OSUR. First Mercantile Trust Co. acquired a new position in shares of OraSure Technologies during the 2nd quarter worth about $104,000. Pinebridge Investments L.P. acquired a new stake in OraSure Technologies in the 2nd quarter valued at about $131,000. Victory Capital Management Inc. raised its holdings in OraSure Technologies by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 1,360 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in OraSure Technologies in the 3rd quarter valued at about $186,000. Finally, Profund Advisors LLC raised its holdings in OraSure Technologies by 2.8% in the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 293 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/11/zacks-analysts-anticipate-orasure-technologies-inc-osur-will-post-quarterly-sales-of-45-27-million.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.